Pig mycoplasma pneumonia live attenuated vaccine and application thereof

A technology of Mycoplasma suis pneumonia and live attenuated vaccine, applied in bacterial antigen components, microorganisms, respiratory system diseases, etc., can solve the problems of difficult to achieve ideal control, high price, unable to completely prevent wild virus infection and other problems

Active Publication Date: 2014-04-23
JIANGSU ACADEMY OF AGRICULTURAL SCIENCES
View PDF1 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Of course, this requires relatively high antigen doses and strong adjuvants, making these vaccines expensive
At the same time, the immune response produced by the inactivated vaccine can only inhibit the proliferation of wild virus infection and reduce the degree of tissue damage, but cannot completely prevent the infection of wild virus, so it is difficult to achieve ideal control of the disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pig mycoplasma pneumonia live attenuated vaccine and application thereof
  • Pig mycoplasma pneumonia live attenuated vaccine and application thereof
  • Pig mycoplasma pneumonia live attenuated vaccine and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Embodiment 1: the acquisition of Mycoplasma hyopneumoniae AN306

[0025] Acquisition of virulent strains:

[0026] In 1975, according to the requirements of the Ministry of Agriculture, the Jiangsu Academy of Agricultural Sciences collected typical disease materials of mycoplasma pneumonia from more than 20 provincial agricultural universities and national and provincial academies of agricultural sciences to screen the virulent pathogenic strains of mycoplasma hyopneumoniae. A total of more than 200 samples of suspected mycoplasma pneumonia pneumonia lung disease were collected from all over the country, and 10 samples with typical mycoplasma hyopneumoniae infection and no obvious other pathogenic infection were screened out, and they were stored as virulent tissue poisons of mycoplasma hyopneumoniae. . Simultaneously, the animal challenge pathogenesis test and the continuous passage attenuation test were carried out.

[0027] The selected 10 highly virulent tissue vi...

Embodiment 2

[0047] Embodiment 2: the cultivation of Mycoplasma hyopneumoniae attenuated strain AN306 strain

[0048] Preparation of KM2 liquid medium (according to 2050mL): Eagles’ solution 1000mL, hydrolyzed milk protein 10g, porcine serum 400mL, fresh yeast extract 20mL, Dulbecco’s phosphate buffer 600mL, penicillin 4 million units, 0.4% phenol red 3.5mL, Use 10g / L NaOH to adjust the pH value to 7.4-7.6.

[0049] Take 1 freeze-dried strain of Mycoplasma hyopneumoniae attenuated strain AN306, dissolve it in 0.5mL medium, inoculate 0.5mL in 4.5mL medium, culture in a closed penicillin bottle at 37°C, when the color of the medium changes from red to yellow Harvest the culture in time, inoculate it into fresh medium at a ratio of 1:10 by volume to expand the culture, harvest the culture in time when the color of the medium changes from red to yellow, expand the culture to 5000mL and harvest the strain accordingly.

[0050] Prepare a lyoprotectant, the formula is 1.5 g of gelatin, 12.5 g of...

Embodiment 3

[0052] Example 3: Immunoprotective evaluation of intrapulmonary injection immunized live attenuated Mycoplasma pneumoniae vaccine AN306 strain and comparison with other commercialized live vaccines and inactivated vaccines

[0053] Vaccine preparation:

[0054] Freeze-dried vaccine of AN306 strain of mycoplasma pneumonia live attenuated vaccine, dissolved in sterile phosphate buffer solution, prepared vaccine solution so that the titer of the live vaccine was 2×10 5 CCU / mL. Inject 0.5 mL into the lungs of each animal, that is, 10 5 CCU / head.

[0055] Commercialized live vaccines: In this experiment, only two live vaccines against Mycoplasma pneumoniae in the market were used as control live vaccines. (1) The live vaccine of Mycoplasma suis pneumonia produced by Jilin Zhengye Biological Products Co., Ltd. is chicken embryo yolk sac tissue containing the attenuated strain of Mycoplasma hyopneumoniae, hereinafter referred to as commercial vaccine 1, and is operated according t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pig mycoplasma pneumonia live attenuated vaccine and application thereof. A pig lung disease material infected by typical pig mycoplasma hyopneumoniae and not infected by other pathogens is screened and then is subcultured to the 100th generation through the lung of a baby rabbit, then pig mycoplasma hyopneumoniae strains are separated and are continuously subcultured through a culture medium; meanwhile, the mycoplasma hyopneumoniae AN306 is obtained through screening of a plurality of strains, and the preservation number of the mycoplasma hyopneumoniae AN306 is CCTCC M2012431. The invention also relates to a pig mycoplasma pneumonia live vaccine preparation based on the preparation of the attenuated vaccine strain. The pig mycoplasma pneumonia live vaccine preparation comprises a live attenuated vaccine strain, a pharmaceutically acceotable carrier or auxiliary ingredient and an adjuvant, and further comprises immunogens of other pathogens. The pig mycoplasma pneumonia live vaccine disclosed by the invention can be immunized in multiple ways and can enable animals to gain protection ability for resisting pig mycoplasma hyopneumoniae infection.

Description

technical field [0001] The invention relates to an attenuated vaccine strain of mycoplasma pneumoniae in swine, a live vaccine containing the attenuated strain, and an application thereof in protecting diseases related to mycoplasma hyopneumoniae infection. Background technique [0002] Mycoplasma hyopneumoniae pneumonia, commonly known as swine asthma, is a chronic respiratory infectious disease of pigs caused by Mycoplasma hyopneumoniae (Mhp). The main symptoms are cough and wheezing. The disease mainly causes the feed conversion rate and growth retardation of pigs, with high morbidity and low mortality. Mycoplasma suis pneumonia is widely prevalent in the world, causing significant economic losses to the modern pig industry. [0003] Mycoplasma hyopneumoniae often forms mixed infections with other pathogens. For example, with Pasteurella Multocida (Pasteurella Multocida), Streptococcus Suis (SS), Haemophilus Parasuis of Swine (HPS) or Actinobacillus Pleuropneumonia of P...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N1/20A61K39/02A61P11/00A61P31/04A61P37/04C12R1/35
Inventor 邵国青熊祺琰刘茂军冯志新韦艳娜王海燕白方方甘源王丽张道华刘冬霞华利忠武昱孜白昀王占伟
Owner JIANGSU ACADEMY OF AGRICULTURAL SCIENCES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap